Aradigm
HomeAboutProductsTechnologiesInvestorsCareers
Events & Presentations

Investor Relations

Press Releases

Scientific Publications

Corporate Governance

Financial Information

Stock Information

Contact Us


Archived Events
Nov 9, 2017
8:00 AM ET
Key Opinion Leader (KOL) Breakfast on the topic of Non-Cystic Fibrosis Bronchiectasis (NCFBE)
Webcast Listen to webcast
Sep 26, 2017
2:00 PM ET
Ladenburg Thalmann 2017 Healthcare Conference
Webcast Listen to webcast


Archived Poster and Speaker Presentations
  2017 ERS Conference: Reduction in Frequency of Pulmonary Exacerbations With Inhaled ARD-3150 in Non-Cystic Fibrosis Bronchiectasis (NCFB) Patients is Independent of Pseudomonas aeruginosa Susceptibility at Baseline PDF 468.9 KB Add to Briefcase
  2017 World BE Conference Healthcare Cost and Utilization Before After Diagnosis Pseudomonas Aeruginosa Among Patients with Non Aeruginosa Among Patients with Non -cystic Fibrosis Bronchiectasis in the U.S. PDF 348.5 KB Add to Briefcase
  2017 World BE Conference The Prevalence of Non -cystic Fibrosis Bronchiectasis in the U.S. PDF 274.6 KB Add to Briefcase
  2017 World BE Conference Treatment Patterns Associated with Pseudomonas Aeruginosa Among Patients with Non Patients with Non -cystic Fibrosis Bronchiectasis in the U.S. PDF 207.3 KB Add to Briefcase
  2017 World BE Conference Inhaled Liposomal Ciprofloxacin in Patients With Non-Cystic Fibrosis Bronchiectasis and Chronic Pseudomonas aeruginosa Infection: Pharmacokinetics of Once-Daily Inhaled ARD-3150 PDF 554.9 KB Add to Briefcase
  2017 ISAM Conference Inhaled Liposomal Ciprofloxacin for the Prevention and Treatment of Severe Intracellular Lung Infections PDF 788.6 KB Add to Briefcase
  2017 World BE Conference Microbiological Results From Two Parallel, Randomized, Double-blind, Placebo-Controlled Phase III Trials (ORBIT-3 and ORBIT-4) of the Inhaled Antibiotic ARD-3150 in Patients With Non-Cystic Fibrosis Bronchiectasis and Chronic Pseudomonas aeruginosa Infection PDF 2.7 MB Add to Briefcase
  2017 ISAM Conference Inhaled Liposomal Ciprofloxacin in Patients With Non-cystic Fibrosis Bronchiectasis and Chronic Pseudomonas aeruginosa Lung Infection PDF 233.8 KB Add to Briefcase
  2017 World BE Conference Inhaled Liposomal Ciprofloxacin in Patients With Bronchiectasis and Chronic Pseudomonas aeruginosa Infection: Results From Two Parallel Phase III Trials (ORBIT-3 and ORBIT-4) PDF 232.7 KB Add to Briefcase
  2016 ATS Conference ORBIT-3 and ORBIT-4: Design of a Phase 3 Program to Investigate Safety and Efficacy of Pulmaquin® in Non-Cystic Fibrosis Bronchiectasis (NCFBE) Patients Chronically Colonized with Pseudomonas Aeruginosa (PA) PDF 241.3 KB Add to Briefcase
  2016 ATS Conference Liposome-Ciprofloxacin inhibits Mycobacterium avium subsp hominissuis (MAH) microaggregate formation in dose and time-related manner PDF 517.3 KB Add to Briefcase
  2015 ISAM Conference Novel Inhaled Liposomal Ciprofloxacin Formulations for Personalized Therapy PDF 429.0 KB Add to Briefcase
  2011 ISAM Conference Deeper Lung Pulmonary Delivery of Treprostinil is Associated with Delayed Systemic Absorption PDF 528.8 KB Add to Briefcase
  2011 ISAM Conference Dual Release Ciprofloxacin for Inhalation Improves Time to First Exacerbation in Bronchiectasis PDF 702.6 KB Add to Briefcase
Add to Briefcase = add file to Briefcase
CONTACT NEWS & EVENTS LEGAL SITE MAP ©2017 Aradigm Corporation. All Rights Reserved.